AbbVie
ABBV
2,002 hedge funds and large institutions have $80.2B invested in AbbVie in 2019 Q3 according to their latest regulatory filings, with 123 funds opening new positions, 858 increasing their positions, 798 reducing their positions, and 124 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 52 → 73 (+21)
5% more capital invested
Capital invested by funds: $76.1B → $80.2B (+$4.1B)
2.12% more ownership
Funds ownership: 69.55% → 71.67% (+2.1%)
8% more repeat investments, than reductions
Existing positions increased: 858 | Existing positions reduced: 798
1% less first-time investments, than exits
New positions opened: 123 | Existing positions closed: 124
1% less funds holding
Funds holding: 2,021 → 2,002 (-19)
7% less call options, than puts
Call options by funds: $1.63B | Put options by funds: $1.75B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$724M |
| 3 |
JP Morgan Chase
New York
|
+$629M |
| 4 |
BlackRock
New York
|
+$229M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$200M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$652M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$457M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$350M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$162M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$143M |
ABBV Hedge Fund Activity: Q3 2019 in Review
2,002 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2019, worth a combined $80.2B — up 5.4% from $76.1B a quarter earlier.
Sellers outnumbered buyers: 124 funds closed out of ABBV and 123 opened new positions — a net loss of 1 holder — while 798 trimmed existing stakes and 858 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $1B. The largest seller was Capital Research Global Investors, cutting an estimated $652M.
- 2,002 institutional investors held AbbVie (ABBV) as of Q3 2019, down from 2,021 in Q2 2019.
- Funds reported $80.2B of AbbVie stock for Q3 2019, up 5.4% quarter-over-quarter.
- 123 funds opened new AbbVie positions in Q3 2019 and 124 closed out, a net change of -1 holder.
- The largest AbbVie buyer in Q3 2019 was T. Rowe Price Associates, an estimated $1B added.
- The largest AbbVie seller in Q3 2019 was Capital Research Global Investors, an estimated $652M sold.
Based on aggregated 13F filings for Q3 2019.